Inovio Pharmaceuticals, Inc.
http://www.inovio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inovio Pharmaceuticals, Inc.
US Studies Hold The Key To COVID-19 Vaccines Race
US demands for 30,000 subject studies and harmonized protocols mean a robust result could arrive soon – but recruitment could still be a challenge.
Itching To Succeed: UNION Buys LEO Pharma’s PDE4 Inhibitor Series
Denmark-based UNION therapeutics has bought LEO Pharma’s PDE4 inhibitor compound series for use in developing treatments for psoriasis and atopic dermatitis.
Finance Watch: One Week Of IPOs Total $818.2m
Relay raises $400m to kick off July’s second big week of US initial public offerings. Also, Ocumension and Immunotech launch Hong Kong IPOs, Amgen invests $421m in BeiGene’s $2.08bn offering, Cytokinetics gets up to $400m in deal and investment funding, and Imvax closes $111m series C round.
Verona Stock Soars After $200m Placement For COPD Drug
The UK biotech will have no problems funding a Phase III program for its nebulized first-in-class COPD therapy ensifentrine as investors old and new flocked to buy into the stock.
Company Information
- Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Bioject Medical Technologies
- Inovio Biomedical
- VGX Pharmaceuticals